REVIEW

Applications of stable, nonradioactive isotope tracers in *in vivo* human metabolic research

Il-Young Kim¹, Sang-Hoon Suh², In-Kyu Lee³ and Robert R Wolfe¹

The human body is in a constant state of turnover, that is, being synthesized, broken down and/or converted to different compounds. The dynamic nature of *in vivo* kinetics of human metabolism at rest and in stressed conditions such as exercise and pathophysiological conditions such as diabetes and cancer can be quantitatively assessed with stable, nonradioactive isotope tracers in conjunction with gas or liquid chromatography mass spectrometry and modeling. Although measurements of metabolite concentrations have been useful as general indicators of one's health status, critical information on *in vivo* kinetics of metabolites such as rates of production, appearance or disappearance of metabolites are not provided. Over the past decades, stable, nonradioactive isotope tracers have been used to provide information on dynamics of specific metabolites. Stable isotope tracers can be used in conjunction with molecular and cellular biology tools, thereby providing an in-depth dynamic assessment of metabolic changes, as well as simultaneous investigation of the molecular basis for the observed kinetic responses. In this review, we will introduce basic principles of stable isotope methodology for tracing *in vivo* kinetics of human or animal metabolism with examples of quantifying certain aspects of *in vivo* kinetics of carbohydrate, lipid and protein metabolism.

Experimental & Molecular Medicine (2016) **48**, e203; doi:10.1038/emm.2015.97; published online 15 January 2016

INTRODUCTION

The human body is in a dynamic homeostasis. In other words, all aspects of the body are in a state of turnover, that is, being synthesized, broken down and/or converted to different compounds. For example, the muscle protein pool size in the body is relatively constant in healthy adults because the continual breakdown of muscle protein is matched by a corresponding synthesis of new muscle protein. A change in pool (for example, protein) size reflects either net synthesis, that is, synthesis exceeding breakdown (for example, muscle hypertrophy) or net breakdown, that is, breakdown exceeding synthesis (for example, cancer cachexia and sarcopenia). This dynamic nature of various aspects of human metabolism can be best explored *in vivo* by the use of stable, nonradioactive tracers with the help of gas or liquid chromatography mass spectrometry (GC/MS or LC/MS). Figure 1 shows a schematic diagram of a human subject participating in a stable isotope tracer infusion. In general, one or more stable isotope tracers are introduced intravenously into the systemic circulation. Most commonly, blood (or other accessible tissues such as muscle and adipose tissues) samples are collected before and

during the tracer infusion. Isotopic enrichment is subsequently determined by means of GC/MS or LC/MS. And finally, the *in vivo* kinetics of the substance being traced ('tracee') is calculated on the basis of the measured ratio of the tracer to tracee in the samples (for example, fractional synthesis rate, *FSR*) or in conjunction with the tracer infusion rate (*F*) (for example, rate of appearance, *R_a*).¹ In this review, we will briefly discuss the following topics: the meaning of metabolic isotope tracer, determination of isotopic enrichment, utilization of GC/MS, performance of a tracer infusion study, mathematic models for estimation of *in vivo* kinetics and biological applications of the tracer techniques. We also provide exemplary calculations of carbohydrate, lipid and protein kinetics as Supplementary Data (S1–6). Our goal is to provide a basic overview for investigators not familiar with the methodology. More comprehensive and detailed reference sources are available.^{1,2} In addition, there is a National Institute of Health/Mouse Metabolic Phenotyping Centers (NIH/MMPC)-sponsored annual Isotope Tracers in Metabolic Research course (<https://www.mmpc.org/shared/tracers.aspx>).

¹Department of Geriatrics, the Center for Translational Research on Aging and Longevity, Donald W. Reynolds Institute on Aging, College of Medicine, The University of Arkansas for Medical Sciences, Little Rock, AR, USA; ²Department of Physical Education, College of Sciences in Education, Yonsei University, Seoul, Republic of Korea and ³Section of Endocrinology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea

Correspondence: Dr I-Y Kim, Department of Geriatrics, the Center for Translational Research on Aging and Longevity, Donald W. Reynolds Institute on Aging, College of Medicine, The University of Arkansas for Medical Sciences, 4301W. Markham Street, #806, Little Rock, AR 72205-7199 USA.

E-mail: iykim@uams.edu

Received 24 August 2015; accepted 6 October 2015

Figure 1 Schematic diagram of human stable isotope infusion study. It is typical that one or more stable isotope tracers are introduced intravenously into the systemic circulation via a catheter placed on one arm. Blood (or other accessible tissues such as muscle and adipose tissues) samples are collected from the other arm (or hand) before and after the tracer infusion. Isotopic enrichment (tracer to tracee ratio, or *TTR*) of a compound of interest is subsequently determined by means of GC/MS.

METABOLIC ISOTOPE TRACERS

A metabolic isotope tracer is a molecule that is chemically and functionally identical to the naturally occurring molecule of interest (that is, tracee), and following the fate of the tracer provides information on the metabolism of the tracee.¹ A metabolic tracer can be a molecule labeled with a stable or radioactive isotope(s). However, potential adverse health effects of radioactivity in human subjects have limited the use of radioactive tracers. In addition, the versatility of stable isotope methodology has greatly expanded the variety of studies possible. Therefore, this review will focus on the applications of stable isotope tracers to explore *in vivo* kinetics of human metabolism.

Stable isotopes

Isotopes are elements that are chemically identical but different in mass because of the differences in the number of neutrons in their nuclei, and are either radioactive or stable, nonradioactive isotopes. As opposed to radioactive isotopes, stable isotopes are naturally occurring and stable over time without undergoing spontaneous decay with emission of radiation. In human metabolic research, the most commonly used stable isotopes include hydrogen, carbon and nitrogen isotopes that can be incorporated into molecules to be used as metabolic tracers. These elements have one or more isotopes with specific natural distribution patterns of abundance. For instance, carbon has two stable isotopes, that is, carbon 12 (^{12}C) and carbon 13 (^{13}C), with natural occurrence of approximately 98.9% and 1.1%, respectively. Owing to the existence of isotopes, there exists a unique distribution pattern of naturally occurring molecules with varying masses. Figure 2 shows the relative abundance of naturally occurring glucose with increasing masses. Because the glucose molecule has six carbons, and each carbon has approximately 1.1% of chance to be ^{13}C , 6.6% of naturally occurring glucose will be glucose with having at

least one ^{13}C . When the abundance of the most abundant form of glucose molecule (typically, the lowest mass, $M+0$; molecular weight 180) is normalized to 100%, relative abundance of glucose with molecular masses of 181 ($M+1$), 182 ($M+2$) and 183 ($M+3$) are 6.9%, 1.4% and 0.1%, respectively (Figure 2).

Metabolic tracers

A stable isotope tracer is a molecule with one or more isotopes with a different mass than the most abundantly occurring mass incorporated somewhere in the molecule. In the case of the most commonly used tracers (that is, C, H and N), the stable isotope tracers are heavier than the most commonly occurring mass. The fact that the tracer is heavier than the tracee allows for determination of the ratio of tracer to tracee (that is, enrichment) by measuring the mass of the molecule of interest. Information on the ratio is generally obtained by using GC/MS, but LC/MS can also be used. The general principles are similar, regardless of the means of measurement; so in this review, we will focus on the more commonly used approach of GC/MS. Regardless of the means of analysis, if a tracer such as $1\text{-}^{13}\text{C}$ -glucose is infused intravenously into the systemic circulation for the determination of R_a glucose in the fasted state, the $1\text{-}^{13}\text{C}$ -glucose is heavier than the most abundant form of naturally occurring glucose (containing only ^{12}C , designated as $M+0$) by 1 mass unit (that is, $M+1$). Measurement of the mass differences between tracer and tracee (unlabeled and $1\text{-}^{13}\text{C}$ -glucose in this example) enables the calculation of *in vivo* kinetics of the tracee. Calculations must account for the existence of naturally occurring heavier isotopes in many elements as discussed above. Thus, some portion of glucose is already $M+1$ (for simplicity, we ignored heavier isotopes of hydrogen and oxygen here). This naturally occurring heavier glucose ($M+1$) cannot be differentiated from the $M+1$ glucose tracer that has been infused (for example, $1\text{-}^{13}\text{C}$ -glucose, or glucose with one heavier carbon isotope in any place). However, this can be typically resolved by subtracting background enrichment from the enrichment of the sample collected after infusion of tracer. There are additional factors that must be accounted for when performing kinetic calculations in stable isotope tracer studies such as skew correction and overlapping spectra,³ but these issues are beyond the scope of this paper. Using metabolic tracers, we can trace many aspects of *in vivo* metabolism. To understand how to determine *in vivo* kinetics of metabolism, it is first necessary to understand how isotopic enrichment is determined, and the enrichment information is used to calculate *in vivo* kinetics.

DETERMINATION OF ISOTOPIC ENRICHMENT

Figure 3 depicts the relationship between tracer and tracee in a steady state during a continuous tracer infusion. In a metabolic study, one or more of isotope tracers are infused into the body intravenously and then samples are frequently collected from which relative concentrations of tracer to tracee (that is, isotope enrichment) are quantified. The ratio of tracer to tracee is used for the calculation of tracee kinetics. Although there are several ways to express isotopic enrichment,¹ tracer to tracee ratio

Figure 2 Distribution pattern of abundance of naturally occurring glucose with increasing mass as a result of presence of heavier isotopes of carbon, hydrogen and oxygen (sources from Scientific Instrument Services. www.sisweb.com).

Figure 3 Conceptual schematic diagrams of isotopic enrichment. The systemic circulation is depicted as rectangular boxes. Assume that one kind of compound (e.g., glucose) exists in circulation, and singly labeled glucose tracer (e.g., $1\text{-}^{13}\text{C}$ -glucose, $M+1$) is administered. (a) Enrichment (e.g., tracer to tracee ratio, TTR) is simply the ratio of concentrations of tracer (red circle) to tracee (black circle), which is the ratio of 8 to 92 ($TTR=0.087$). (b) Some proportion of tracee is actually heavier than the most abundant form (typically, $M+0$). For example, 6.9% of naturally occurring glucose has mass of 181 ($M+1$, blue circle) when $M+0$ glucose is normalized to 100%. Because MS does not distinguish $M+1$ of tracee from $M+1$ of tracer, correction needs to be made by subtracting background enrichment from sample enrichment.

(TTR or t/T) is the most widely used. The expression of isotopic enrichment as *atom percent excess* or *mole percent excess* (MPE) is also common. These latter expressions of enrichment are derivatives of TTR , as both *atom percent excess* and MPE (%) are expressed as $TTR/(1+TTR) \times 100$. *Atom percent excess* and MPE are typically used when information on total R_a (R_a tracee + R_a tracer) is needed as in the case for the calculation

of glucose kinetics,^{3–5} protein synthesis⁶ and substrate oxidation.⁷ Exemplary calculations of isotope enrichment are shown in Supplementary Data (S1). This example illustrates determination of isotope enrichment of $6,6\text{-}^2\text{H}_2$ -glucose tracer (a glucose tracer in which two hydrogens attached to six carbons are deuterium) from blood samples collected before and after the tracer infusion, and samples are analyzed using GC/MS. In the following section, we will briefly discuss how GC/MS is used to determine enrichment.

GAS CHROMATOGRAPHY MASS SPECTROMETRY

Figure 4 depicts a schematic representation of a GC/MS. Here, we briefly introduce how to utilize GC/MS for the determination of isotopic enrichment.¹ For more comprehensive information, refer to other sources.^{8–10}

Gas chromatography (GC)

The primary function of GC is to separate the compound of interest from others in a sample mixture and to introduce one compound at a time into the MS. Before injection into the GC, it is typical to process a sample mixture for better GC/MS results, including chemical derivatization of the compound.¹¹ The derivatization is necessary to make the sample volatile with modest heating for GC analysis. The processed sample mixture is then injected into GC where individual compounds in the mixture migrate at different rates through the GC column via a carrier gas (typically, helium) depending on their chemical characteristics.⁹

Mass spectrometry (MS)

The primary function of MS is to quantify the abundance of a specific mass of ion that is fragmented from either unlabeled or labeled compounds of interest in a process of ionization in ion source of the MS via either electron impact ionization (generating fragmentations to a great extent) or chemical impact ionization.¹ After passing through the ionization source, fragmented ions with specific mass/charge (m/z) values can travel through the mass analyzer (or mass filter) for a given set time and hit the electron multiplier (or photomultiplier).¹ For biological samples, the charge is generally one, so samples are separated entirely on the basis of mass. The photomultiplier generates a signal, the intensity of which is directly proportional to the abundance of the ions.⁹ Figure 5 shows the total ion chromatogram and mass spectrum of ions of the pentaacetate derivative of glucose after chemical impact ionization. For determination of isotopic enrichment, a good ion fragment for monitoring must be identified. Then, the selected ion fragment can be monitored using selected ion monitoring.⁹ As its name implies, selected ion monitoring monitors only a few selected number of masses from fragmented ions rather than monitoring the ions for all m/z , which increases specificity and thus improves the detection limit.⁹ In stable isotope research, infusion of an isotope tracer with one or more of labels (for example, $1\text{-}^{13}\text{C}$ -glucose, $M+1$) will increase the abundance of ions with a mass increase ($M+1$). In this case, TTR will be the background-subtracted

Figure 4 Schematic diagram of a gas chromatography quadrupole mass spectrometer (GC/MS).

Figure 5 (a) Total ion chromatogram (TIC), each peak generally representing different compounds, eluting from GC at different time and (b) mass spectrum, showing abundance of ions with varying masses (heavier toward right) due to fragmentations of the compound, each peak from TIC is the sum of abundance from all the ions in its mass spectrum.

ratio of $M+i$ to $M+0$ ($M+i$, molecule with i mass unit above $M+0$). For more detailed explanation, refer to additional sources.^{1,12}

Isotope ratio MS

The isotope ratio MS is commonly used to analyze enrichment of gases such as N_2 , O_2 and CO_2 .¹ In metabolic studies, the isotope ratio MS is typically used for the determination of $^{13}CO_2$ enrichment in the breath sample collected after administration of ^{13}C -labeled substrate such as 1- ^{13}C -glucose, U- $^{13}C_6$ -glucose, 1- ^{13}C -palmitate and U- $^{13}C_{16}$ -palmitate (the U- refers to the fact that the molecule is uniformly labeled, meaning that all carbons are enriched with carbon 13) for estimating the rate of substrate oxidation in conjunction with indirect calorimetry. For example, breath CO_2 enrichment can be determined (ratio of $^{13}CO_2$ to $^{12}CO_2$) after infusion of a

^{13}C -labeled tracer to determine the rates of oxidation of specific components of carbohydrate (for example, glucose)^{13,14} and lipids (for example, oleate and palmitate).^{5,15} The rate of oxidation of individual amino acids (AA) that can be oxidized in tissues such as muscle (that is, leucine) can also be determined with ^{13}C -labeled tracers.^{16,17} We will provide an example of the calculation of substrate oxidation later in this review (Supplementary Data (S6)). Before this, we will touch briefly on the mathematical models used for the estimation of kinetics of various tracers.

MATHEMATICAL MODELS

In a general sense, the mathematical models used to calculate tracer kinetics can be collectively divided into two main categories: (i) tracer dilution model and (ii) tracer incorporation model.

Figure 6 Schematic rationale for the determination of R_a tracee using a stable isotope tracer method in a physiological steady state. Before (a) and throughout a tracer infusion (b, c and d), R_a tracee will be equal to R_d tracee, both of which are being constant in a steady state (d). To estimate R_a tracee, a tracer is primed continuously infused intravenously. At the beginning of the infusion, rate of removal of tracer from the compartment (b and c) is lower than tracer infusion rate (F). However, it will be eventually equal over time to F (d). Red and black circles represent tracee and tracer, respectively. For simplicity, naturally occurring heavier glucose molecules were ignored.

Tracer dilution model

The dilution model can be useful for the determination of tracee kinetics both in a steady state and in a nonsteady state. In a physiological steady state, for example, glucose concentrations are constant over time, which means that the rate that glucose appears (R_a glucose) into blood from all sources is equal to the rate that glucose disappears (R_d glucose) from the blood. With a primed continuous infusion, the magnitude of dilution of this isotope tracer by tracee in the plasma compartment at an isotopic steady state reflects R_a tracee of interest in plasma (in this example, glucose). This calculation does not account for the total production (if any) of tracee in compartments where the tracee is produced without appearing into plasma.^{1,2} The dilution model has been widely used for the calculation of tracee, including glucose,^{3–5,13,14,18} fatty acid,^{5,15,18} glycerol^{7,19} and lactate^{20,21} in steady states and nonsteady states. Contrary to steady-state conditions, it is more complex to calculate the kinetics in nonsteady-state conditions such as during a meal feeding or exercise. The most important calculation for nonsteady-state kinetics was carried out by Steele in 1959 to investigate glucose metabolism in a situation where insulin was injected.²² The so-called ‘Steele’ equation has been extensively used for nonsteady-state calculations of *in vivo* kinetics of glucose,^{3,4,13,14} free fatty acids (FFA),^{5,15,23} glycerol^{23,24} and lactate,^{20,25} since that pioneering study. The Steele equation is derived for the use with compounds that are either distributed in a single pool, or can be described as if the sampled compartment represents a fraction of a single pool. Because of the complexity of calculating kinetics in the nonsteady state, we will focus mainly on the use of the tracer dilution model for steady-state conditions.

Rationale for calculation of rate of appearance of tracee in steady-state conditions. In a steady state, the blood concentration of the tracee of interest is constant. This is because the rate at which the tracee appears in the blood is equal to the rate at which it disappears from the blood. Figure 6 is a schematic representation of the relationship between R_a tracee, F and TTR in a physiological steady state. Figure 6a depicts a condition before tracer infusion with the assumption that R_a glucose is $10 \mu\text{mol kg}^{-1} \text{min}^{-1}$. In an actual experiment, R_a glucose would be the unknown and it would be calculated using tracer methodology. As R_a is equal to R_d in a steady state, we know in this example that R_d glucose must also be $10 \mu\text{mol kg}^{-1} \text{min}^{-1}$. To determine R_a glucose, a glucose tracer is started at a rate (for example) of $0.42 \mu\text{mol kg}^{-1} \text{min}^{-1}$ (Figure 6b). Several general assumptions in this model must be satisfied:¹ (i) the infused tracer does not affect the endogenous metabolism of tracee of interest, (ii) the infused tracer does not reappear in the sampled compartment (for example, blood) to which the tracer initially infused and then removed from the compartment, and (iii) the body does not distinguish between tracer and tracee, and therefore removal of the tracer and tracee depends on their relative concentrations in the compartment, and others. In Figure 6b, although R_a glucose is equal to R_d glucose, F is higher than the rate of tracer removal from the

sampled compartment at the beginning of the tracer infusion. However, the rate of tracer removal will eventually become equal to F (Figure 6d). Over time, TTR will increase as seen in Figure 6 (order of time sequence: 6a $\rightarrow$ 6b $\rightarrow$ 6c), and then will plateau when F is equal to the rate of tracer removal rate (Figure 6d), at which it is called enrichment at isotopic equilibrium, or plateau enrichment (E_p). Once the F and E_p are known, R_a tracee can be calculated by dividing F by E_p . For a given F , R_a tracee will be inversely related to E_p , such that R_a tracee will be higher if the measured value for E_p is lower. Although in this schematic, we describe the relations with a continuous tracer infusion, the basic idea will be the same with injection of a priming dose. In the case of the primed continuous infusion of tracer, the time to achieve E_p is reduced. An appropriate priming dose can be determined from previous experiments reported in the literature, or by performing a preliminary study before start of a new stable isotope tracer study. The approach to calculating an appropriate priming dose is described elsewhere.¹

Derivation of steady-state kinetic equations. Assuming that the infusion of a tracer does not affect endogenous metabolism of the tracee of interest, the relation between R_a tracee, F and TTR at a steady state can be mathematically derived:¹

$$\begin{aligned} R_a \text{ tracee}(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1})/F(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}) \\ = \text{tracee}(\mu\text{mol}\cdot\text{l}^{-1})/\text{tracer}(\mu\text{mol}\cdot\text{l}^{-1}) \end{aligned} \quad (1)$$

After rearranging the equation (1) for R_a tracee,

$$\begin{aligned} R_a \text{ tracee}(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}) \\ = F(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}) \times [\text{tracee}(\mu\text{mol}\cdot\text{l}^{-1})/\text{tracer}(\mu\text{mol}\cdot\text{l}^{-1})] \end{aligned} \quad (2)$$

By canceling the units of denominator and numerator on the right part of the equation [$\text{tracee}(\mu\text{mol}\cdot\text{l}^{-1})/\text{tracer}(\mu\text{mol}\cdot\text{l}^{-1})$] equation (2), and because reciprocal of tracee/tracer is TTR , the equation (2) can be written as:

$$\begin{aligned} R_a \text{ tracee}(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}) \\ = F(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1})/TTR \end{aligned} \quad (3)$$

Because TTR at isotopic equilibrium is called plateau isotopic enrichment (E_p), the equation (3) can be written as:

$$\begin{aligned} R_a \text{ tracee}(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}) \\ = F(\mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1})/E_p \end{aligned} \quad (4)$$

Tracer incorporation model

The incorporation model is based on the rate of incorporation of precursor tracer into product over a given time. This yields a FSR , which is commonly expressed as %/h. This value (after converting from % to fractional value) must be multiplied by the total pool size to derive an absolute synthesis rate. As with any model of kinetics, there are several assumptions with the incorporation model, including that the pool size of the product and rate of incorporation of precursor for the early

time after the start of the tracer infusion is constant.^{1,2} Many investigators have used *precursor-product models* to estimate FSR .^{2,26} For example, when determining the rate of protein synthesis, precursors are AA and proteins are products. Using this incorporation model, the kinetics of various compounds can be determined including FSR of individual proteins²⁷ and subgroups of proteins (mitochondrial, sarcoplasmic and mixed muscle protein),^{6,28} substrate oxidation rate,⁵ DNA synthesis rate (thus cell division)^{29,30} and nitric oxide synthesis rate from the precursor arginine.^{31,32}

PERFORMING ISOTOPE TRACER INFUSION STUDY

Catheterization

Before starting a tracer infusion study, catheters are generally placed in peripheral veins in the arms: one for infusion of tracers and the other in the contralateral arm for blood sampling. However, when a sample needs to come from an artery such as in an arteriovenous balance study, a catheter needs to be placed directly in an artery.³³ Arterial catheterization has certain inherent risks, particularly in vulnerable populations.³⁴ Alternatively, the 'heated-hand' technique in which a hand vein is typically warmed to $\sim 65^\circ\text{C}$ for ~ 10 min can be used to obtain an 'arterialized' blood sample, which enables the measurement of values that approximate those in true arterial blood.^{35,36}

Tracer administration method

Upon appropriate catheterization, one or more of tracers can be introduced into the circulation by either oral ingestion or intravenous infusion or injection. Intravenous administration is most common. The most commonly used method is the 'primed continuous (constant) infusion' method. In this method, an appropriate priming dose of tracer is intravenously injected as a bolus to hasten achieving a plateau in enrichment, followed by a continuous infusion at a rate that is generally chosen to produce E_p of less than 0.10. A greater abundance of tracer could potentially alter the endogenous metabolism of tracee. It is optimal to achieve enrichment as low as possible within the detection limits of the GC/MS, thereby reducing the possibility of altering the endogenous metabolism of the tracee. A lower infusion rate also has the benefit of requiring less tracer, thereby reducing the cost. Without priming, E_p will still be achieved eventually, but it will take a much longer time. Lengthening the infusion time may present logistical problems in human research, and also impact the physiological state. After finishing an infusion study, isotopic enrichment in the samples will be determined and used for the calculation of kinetics of the tracee of interest. In the following section, we will briefly discuss some of the biological aspects that we could trace with use of stable isotope tracer.

BIOLOGICAL APPLICATIONS

Here, we briefly discuss the biological applications of stable isotope tracer methodology with respect to *in vivo* dynamics (kinetics) of carbohydrate, lipid and protein metabolism. These examples are chosen primarily for the purpose of illustrating

the type of questions that can be addressed with tracer methodology.

Glucose kinetics

Under normal conditions, the blood glucose concentration in the fasted state in healthy individuals is fairly constant over time, which is accomplished through a close matching between rate of appearance (R_a) in and rate of disappearance (R_d) of glucose from the circulation. In clinical conditions such as obesity and type 2 diabetes mellitus, however, alterations in glucose kinetics are apparent.³⁷ Briefly, R_a glucose is derived mainly from hepatic glucose production (via glycogenolysis and gluconeogenesis) and to a minor extent from renal gluconeogenesis. Fates of R_d glucose includes glycolysis, mitochondrial oxidation, glycogen synthesis and other metabolic pathways. These dynamics of *in vivo* glucose metabolism can be best quantified with the use of stable isotope tracer methodology. Here, we will discuss some aspects of *in vivo* kinetics of glucose metabolism. To determine glucose kinetics in a steady state, a glucose tracer (for example, 1-¹³C-glucose as in Example 2) is continuously infused intravenously following a bolus injection of the same tracer (priming dose). Plasma samples are collected before the tracer infusion and a couple of times after achieving isotopic equilibrium for determination of the steady-state kinetics of the tracee. Exemplary calculations of R_a and R_d glucose in a steady state are shown in Supplementary Data (S2). Owing to the existence of substrate cycles at several steps of glycolysis such as the glucose cycle during which the loss of isotope label occurs without net conversion of precursor to product, an appropriate selection of glucose tracer is crucial for the accurate quantification of glucose kinetics.³⁸

Lipid kinetics

Lipids comprise more than 80% of the body's stored fuel energy as triacylglycerols (TAG), mainly in adipose tissue. Body fat turns over continuously, and the fat mass is the direct result of the balance between synthesis and removal (that is, turnover) of TAG, and alterations in TAG turnover can lead to metabolic complications such as obesity and dyslipidemia. Briefly, TAG is broken down to three FFA and one glycerol through a series of enzyme reactions including hormone-sensitive lipase.³⁹ The process is called lipolysis. Fatty acids released from TAG can be either released into systemic circulation or used for resynthesis of TAG (adipocyte re-esterification or 'intracellular' recycling) with incorporation of glycerol phosphate generated from glycolysis in the adipocyte. Fatty acids released into the circulation are cleared by tissues where they can be oxidized into CO₂ and H₂O for ATP resynthesis or re-esterified into TAG ('extracellular recycling'). Contrary to the fates of FFA, glycerol released from TAG cannot directly participate in TAG re-esterification but instead is released into the systemic circulation because of the lack of glycerol kinase in tissues other than liver, which converts glycerol to glycerol phosphate, a required step for re-esterification. Thus, R_a glycerol is a direct reflection of the rate of lipolysis at the whole-body level, which can therefore be

quantified by tracing R_a glycerol into the circulation using a glycerol tracer.¹ Further, with a simultaneous infusion of a palmitate tracer along with an infusion of a glycerol tracer, intracellular, extracellular and total (intra+extra-cellular) recycling rates can be calculated.⁴⁰ Exemplary calculations of lipolysis, fatty acid turnovers (R_a and R_d), and substrate cycling are shown in Supplementary Data (S3). Briefly, 1-¹³C-palmitate is constantly infused without a priming dose because of the rapidly mixing plasma pool and its rapid turnover rate⁴¹ while primed continuous infusion of [1,1,2,3,3-²H₂]-glycerol is simultaneously performed. R_a palmitate and R_a glycerol (or rate of lipolysis) are determined as the infusion rate of the respective tracer divided by plateau enrichment (E_p) in the plasma. Then R_a FFA is estimated as R_a palmitate divided by the fractional contribution of palmitate to total FFA, which is reported to be approximately 0.65 (or 65%) at rest.⁴² Now, the intracellular recycling or re-esterification rate is determined as three times R_a glycerol (lipolysis) minus R_a palmitate, because the stoichiometry between FFA and glycerol is 3:1 per lipolysis. Extracellular recycling rate is determined as R_a FFA minus FFA oxidation rate (discussed later in the section Substrate oxidation and Supplementary Data (S6)). Finally, the total recycling rate is determined as the sum rates of intracellular and extracellular recycling where total recycling rate = $3 \times R_a$ glycerol – FFA oxidation rate.

Protein kinetics

The amount of protein in the body (the protein pool size) is relatively constant because the rates of protein synthesis and breakdown are closely matched over time in normal healthy adults. However, the protein pool size can change as a result of normal or pathological processes, for example, resistance exercise with sound nutrition (hypertrophy), age-associated loss of muscle mass (that is, sarcopenia) or diseases (for example, cancer cachexia).⁴³ Simultaneous quantifications of protein synthesis and breakdown at individual protein, tissue and whole-body levels are therefore of primary importance for understanding a complete picture of protein metabolism. For example, there is a progressive loss of muscle mass (protein) in certain clinical conditions such as burn injury and cancer cachexia as a result of protein breakdown exceeding synthesis.⁴³ As opposed to our initial intuition, protein synthesis is typically elevated in these clinical conditions. This increase in protein synthesis is actually secondary to an increase in protein breakdown because AA derived from protein breakdown provides building blocks for ~80% of newly synthesized proteins.¹ First, we will discuss a representative method among others for exploring *in vivo* whole-body kinetics of protein turnover. Here, we will discuss an essential AA (EAA) tracer method.⁶ The general approach is fundamentally based on the determination of the R_a into and the R_d from plasma of an EAA such as phenylalanine. For example, R_a of any EAA reflects the rate of protein breakdown in the fasted state because protein breakdown is the sole source of EAAs released into the plasma, because EAAs are not produced in the body.¹ Therefore, in post-absorptive states, the rate of protein

breakdown can be estimated by dividing R_a of any EAA by its fractional contribution to protein.⁴⁴ Fates of R_d EAA include protein synthesis and oxidation (or hydroxylation of phenylalanine to tyrosine in the case of phenylalanine). With an additional determination of EAA oxidation in the post-absorptive state where R_a is equal to R_d , the rate of protein synthesis can be quantified as R_d minus the EAA oxidation (or hydroxylation) rate. Exemplary calculations of whole-body protein kinetics using phenylalanine and tyrosine tracers are shown in Supplementary Data (S4).^{6,45} In this case, we assume that contribution of phenylalanine to protein is 4%.⁴⁴ For example, L-[ring-²H₅]-phenylalanine and L-[ring-²H₂]-tyrosine are primed continuously infused. To appropriately reach isotopic equilibrium of L-[ring-²H₄]-tyrosine derived from L-[ring-²H₅]-phenylalanine infused (via hydroxylation reaction), a priming dose of L-[ring-²H₄]-tyrosine is also administered. Blood samples are collected before the tracer infusion and after reaching E_p . R_a phenylalanine and R_a tyrosine are determined as F divided by E_p . Hydroxylation rate is determined as fraction of R_a tyrosine derived from phenylalanine times R_a tyrosine. Using these kinetic values (that is, R_a tracee and hydroxylation rate), we can calculate the rate of protein synthesis (PS), protein breakdown (PB), and thus net protein balance ($NB = PS - PB$) at the whole-body level. Because fates of R_d phenylalanine ($R_a = R_d$ at a steady state) are PS and hydroxylation to tyrosine, PS is calculated as follows: subtraction of the hydroxylation rate from R_d phenylalanine, then divided by 0.04, reflecting the fractional contribution of phenylalanine to protein.⁴⁴ PB is directly reflected by R_d phenylalanine divided by 0.04. Finally, NB is the balance between PS and PB (that is, $NB = PS - PB$). It is important to note that MPE must be used for calculations of all the components of PS because both tracee and tracer are used for the process of synthesis, whereas TTR must be used for calculations of those of PB because tracee, but not tracer, is derived from PB . Second, protein kinetics can be quantified at the tissue (for example, muscle) level. Using the tracer incorporation method, the FSR and the fractional breakdown rate of tissue proteins are accessible but not at the same time frame. It is possible to determine simultaneously both protein synthesis and breakdown at the organ level with an arteriovenous balance technique and stable isotope tracers.^{33,44,46,47} However, this method has inherent invasiveness and needs the determination of regional blood flow, which is often variable.^{33,46–48} Muscle protein synthesis rate can be measured as the FSR using the precursor-product method.²⁶ The method can also be used for the determination of individual protein FSR after extracting the protein of interest,⁴⁹ but not for fractional breakdown rate because originations (specific protein) of products (AAs) for fractional breakdown rate are uncertain. Protein FSR is the fraction of the total protein pool size that has been newly synthesized in a given time. The FSR method is not limited to protein in its application but also to others including DNA, which reflects the cell division rate.^{29,50} Because FSR is a fractional term, the determination of the absolute synthesis rate requires knowledge of the pool size (that

is, $FSR \times \text{pool size}$). Because the pool size is generally constant throughout the time period of a typical metabolic study (typically ≤ 8 h) for slowly turning-over compounds such as muscle protein, FSR can be used for direct comparisons. Exemplary calculations of muscle protein FSR are shown in Supplementary Data (S5). Protein FSR is calculated typically as changes in a representative EAA isotopic enrichment in bound proteins between two time points divided by the mean precursor enrichment of the representative EAA.¹ Because of the difficulties in accessing true precursor enrichment (that is, tRNA charged with AAs),^{51,52} it is common to use surrogate precursor enrichment such as intracellular²⁶ or plasma AA enrichment.⁶ Plasma AA enrichment is more appropriate when the protocol involves both fasted and fed periods.^{1,6}

Substrate oxidation

Quantifying rates of oxidation of substrates such as glucose, fatty acids and AA has long been of interest. For example, alterations in substrate oxidation such as reduced capacity to oxidize fatty acids are linked to various metabolic disorders such as insulin resistance.^{53,54} Stable isotope tracers in conjunction with traditional indirect calorimetry (for the determination of volume of carbon dioxide produced per unit time, VCO_2) have been used to determine the rates of oxidation of specific components of carbohydrate or lipid as well as of protein at various metabolic conditions, including at rest or during exercise at various intensities in healthy^{5,7} or in clinical conditions.^{55,56} The determination of the substrate oxidation rate is based on the incorporation into CO_2 ($^{12}CO_2$ from tracee and $^{13}CO_2$ from tracer) from carbons of substrate of interest such as glucose,^{14,18} free fatty acids (for example, palmitate)^{18,57} or AA (for example, leucine).¹⁷ Exemplary calculations of FFA oxidation using a ^{13}C -labeled palmitate tracer are shown in Supplementary Data (S6). A ^{13}C -labeled tracer is primed continuously infused, and blood samples (for the determination of plasma enrichment of substrate of interest) and breath samples (for the determination of breath CO_2 enrichment) are obtained before the tracer infusion and after plateau enrichment is achieved. From this, the following information can be obtained: (i) percent of substrate uptake oxidized via Krebs cycle (% Uptake Oxidized), (ii) substrate oxidation rate and (iii) percent of total CO_2 production from oxidation of substrate of interest (% CO_2 from oxidation). For example, to determine the rate of palmitate oxidation in a fasted resting state, a ^{13}C -labeled palmitate tracer (for example, 1- ^{13}C -palmitate) can be infused via the primed continuous infusion method (Supplementary Data (S6)). Breath and plasma samples are obtained before start of the tracer infusion and then at isotopic enrichment, from which tracer enrichments are determined. Calculation of the following steady-state kinetics is possible: % uptake oxidized can be calculated as labeled CO_2 enrichment from breath sample times total CO_2 production (determined by indirect calorimetry) divided by plasma enrichment of the tracer infused. In a steady state, R_a palmitate is equal to R_d palmitate, which can be determined as the infusion rate of tracer (F) divided by plateau enrichment

(E_p). Using this information, palmitate oxidation rate can be calculated as R_d palmitate multiplied by % uptake oxidized divided by 100. If a multiple-labeled tracer is used, correction must be made by dividing the value by the number of labeled carbons when the results are expressed as mmol min^{-1} . To calculate total FFA oxidation rate, the rate of palmitate oxidation is divided by the fraction of palmitate in total fatty acids. As not all the carbon produced at the cellular level appears in the circulation because of CO_2 retention in the body, as well as loss of carbon label via isotopic exchange in Krebs cycle, a correction of the rate of $^{13}\text{CO}_2$ should be made, which is typically performed by dividing fractional recovery of $^{13}\text{CO}_2$ obtained from infused carbon labeled acetate.^{58,59}

Summary

Application of stable isotope tracers in metabolic studies in humans enables the quantification of *in vivo* metabolic kinetics in both normal and pathophysiological circumstances. The use of stable isotope tracers are not limited to human studies, but can be used successfully in animal and *in vitro* models as well. However, given the safety of the methodology, it is particularly well suited for clinical studies in human subjects. Stable isotope tracers can be successfully used in conjunction with molecular and cellular biology tools, thereby providing an in-depth dynamic assessment of metabolic changes, as well as simultaneous investigation of the molecular basis for the observed kinetic responses.

CONFLICT OF INTEREST

Dr Robert R Wolfe is a course director of the NIH/MMPC sponsored isotope tracer course. The other authors have no conflict of interest.

ACKNOWLEDGEMENTS

This project was financially supported by Pepper Center Grant PG30-AG-028718 and Award Number UL1-TR-000039 and KL2-TR-000063 from the National Center for Advancing Translational Sciences (NCATS). We appreciate following reviewers: Jiyeon Jung (the University of Connecticut), Sanghee Park (East Carolina University), Yanghoon Jung (Texas A&M) and Dr Bryce J. Marquis (The University of Arkansas for Medical Sciences), for their review with invaluable feedback on the manuscript.

Author contributions: IK prepared figures and drafted manuscript; IK, IL, SS and RRW discussed, edited and approved the final manuscript.

- 1 Wolfe RR, Chinkes DL. *Isotope Tracers in Metabolic Research*. 2nd ed. John Wiley & Sons, Inc.: Hoboken, New Jersey, USA, 2005.
- 2 Cobelli C, Foster D, Toffolo G. *Tracer Kinetics in Biomedical Research*. Kluwer Academic Publishers: Boston, USA, 2001.
- 3 Suh S-H, Casazza GA, Horning MA, Miller BF, Brooks GA. Effects of oral contraceptives on glucose flux and substrate oxidation rates during rest and exercise. *J Appl Physiol* 2003; **94**: 285–294.
- 4 Kim I-Y, Williams RH, Schutzler SE, Lasley CJ, Bodenner DL, Wolfe RR *et al*. Acute lysine supplementation does not improve hepatic or peripheral insulin sensitivity in older, overweight individuals. *Nutr Metab (Lond)* 2014; **11**: 49.
- 5 Romijn JA, Coyle EF, Sidossis LS, Rosenblatt J, Wolfe RR. Substrate metabolism during different exercise intensities in endurance-trained women. *J Appl Physiol* 2000; **88**: 1707–1714.

- 6 Kim I-Y, Schutzler S, Schrader A, Spencer H, Kortebein P, Deutz NEP *et al*. Quantity of dietary protein intake, but not pattern of intake, affects net protein balance primarily through differences in protein synthesis in older adults. *Am J Physiol Endocrinol Metab* 2015; **308**: E21–E28.
- 7 Jacobs KA, Casazza GA, Suh S-H, Horning MA, Brooks GA. Fatty acid reesterification but not oxidation is increased by oral contraceptive use in women. *J Appl Physiol* 2005; **98**: 1720–1731.
- 8 Watson TJ, Sparkman DO. *Introduction to Mass Spectrometry*, 4 ed. John Wiley & Sons, Ltd: Chichester, England, 2007.
- 9 Sparkman DO, Penton ZE, Kitson FG. *Gas Chromatography and Mass Spectrometry*, 2nd ed. Elsevier Inc.: Burlington, MA, USA, 2010.
- 10 Smith MR. *Understanding Mass Spectra*, 2nd ed. John Wiley & Sons: Hoboken, New Jersey, USA, 2004.
- 11 Knapp DR. *Handbook of Analytical Derivatization Reactions*. John Wiley & Sons: New York, 1979.
- 12 Rosenblatt J, Chinkes D, Wolfe M, Wolfe RR. Stable isotope tracer analysis by GC-MS, including quantification of isotopomer effects. *Am J Physiol* 1992; **263**: E584–E596.
- 13 Jeukendrup AE, Raben A, Gijsen A, Stegen JH, Brouns F, Saris WH *et al*. Glucose kinetics during prolonged exercise in highly trained human subjects: effect of glucose ingestion. *J Physiol (Lond)* 1999; **515**(Pt 2): 579–589.
- 14 Coggan AR, Kohrt WM, Spina RJ, Bier DM, Holloszy JO. Endurance training decreases plasma glucose turnover and oxidation during moderate-intensity exercise in men. *J Appl Physiol* 1990; **68**: 990–996.
- 15 Sidossis LS, Stuart CA, Shulman GI, Lopaschuk GD, Wolfe RR. Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. *J Clin Invest* 1996; **98**: 2244–2250.
- 16 Stuart CA, Shangraw RE, Peters EJ, Wolfe RR. Effect of dietary protein on bed-rest-related changes in whole-body-protein synthesis. *Am J Clin Nutr* 1990; **52**: 509–514.
- 17 Hartl WH, Miyoshi H, Jahoor F, Klein S, Elahi D, Wolfe RR. Bradykinin attenuates glucagon-induced leucine oxidation in humans. *Am J Physiol* 1990; **259**: E239–E245.
- 18 Goodpaster BH, Wolfe RR, Kelley DE. Effects of obesity on substrate utilization during exercise. *Obes Res* 2002; **10**: 575–584.
- 19 Baba H, Zhang XJ, Wolfe RR. Glycerol gluconeogenesis in fasting humans. *Nutrition* 1995; **11**: 149–153.
- 20 Miller BF, Fattor JA, Jacobs KA, Horning MA, Navazio F, Lindinger MI *et al*. Lactate and glucose interactions during rest and exercise in men: effect of exogenous lactate infusion. *J Physiol (Lond)* 2002; **544**: 963–975.
- 21 Romijn JA, Chinkes DL, Schwarz JM, Wolfe RR. Lactate-pyruvate inter-conversion in blood: implications for *in vivo* tracer studies. *Am J Physiol* 1994; **266**: E334–E340.
- 22 Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. *Ann N Y Acad Sci* 1959; **82**: 420–430.
- 23 Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Enderby E *et al*. Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. *Am J Physiol* 1993; **265**: E380–E391.
- 24 Klein S, Weber JM, Coyle EF, Wolfe RR. Effect of endurance training on glycerol kinetics during strenuous exercise in humans. *Metab Clin Exp* 1996; **45**: 357–361.
- 25 Messonnier LA, Emhoff C-AW, Fattor JA, Horning MA, Carlson TJ, Brooks GA. Lactate kinetics at the lactate threshold in trained and untrained men. *J Appl Physiol* 2013; **114**: 1593–1602.
- 26 Baumann PQ, Stirewalt WS, O'Rourke BD, Howard D, Nair KS. Precursor pools of protein synthesis: a stable isotope study in a swine model. *Am J Physiol* 1994; **267**: E203–E209.
- 27 Jaleel A, Short KR, Asmann YW, Klaus KA, Morse DM, Ford GC *et al*. *In vivo* measurement of synthesis rate of individual skeletal muscle mitochondrial proteins. *Am J Physiol Endocrinol Metab* 2008; **295**: E1255–E1268.
- 28 Burd NA, Andrews RJ, West DWD, Little JP, Cochran AJR, Hector AJ *et al*. Muscle time under tension during resistance exercise stimulates differential muscle protein sub-fractional synthetic responses in men. *J Physiol (Lond)* 2012; **590**: 351–362.
- 29 Martini WZ, Chinkes DL, Wolfe RR. Quantification of DNA synthesis from different pathways in cultured human fibroblasts and myocytes. *Metab Clin Exp* 2004; **53**: 128–133.
- 30 Strawford A, Antelo F, Christiansen M, Hellerstein MK. Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with $^2\text{H}_2\text{O}$. *Am J Physiol Endocrinol Metab* 2004; **286**: E577–E588.

- 31 Luiking YC, Poeze M, Deutz NE. Arginine infusion in patients with septic shock increases nitric oxide production without haemodynamic instability. *Clin Sci* 2015; **128**: 57–67.
- 32 Castillo L, Beaumier L, Ajami AM, Young VR. Whole body nitric oxide synthesis in healthy men determined from [15N] arginine-to-[15N]citrulline labeling. *Proc Natl Acad Sci USA* 1996; **93**: 11460–11465.
- 33 Biolo G, Declan Fleming RY, Wolfe RR. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. *J Clin Invest* 1995; **95**: 811–819.
- 34 Wolfe RR. *Radioactive and Stable Isotope Tracers in Biomedicine* 1st ed. Wiley-Liss, Inc: New York, NY, USA, 1992.
- 35 McGuire EA, Helderman JH, Tobin JD, Andres R, Berman M. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. *J Appl Physiol* 1976; **41**: 565–573.
- 36 Henderson GC, Fattor JA, Horning MA, Faghihnia N, Johnson ML, Mau TL *et al*. Lipolysis and fatty acid metabolism in men and women during the postexercise recovery period. *J Physiol (Lond)* 2007; **584**: 963–981.
- 37 Radziuk J, Pye S. Production and metabolic clearance of glucose under basal conditions in Type II (non-insulin-dependent) diabetes mellitus. *Diabetologia* 2001; **44**: 983–991.
- 38 Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effect of severe burn injury on substrate cycling by glucose and fatty acids. *N Engl J Med* 1987; **317**: 403–408.
- 39 Jaworski K, Sarkadi-Nagy E, Duncan RE, Ahmadian M, Sul HS. Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. *Am J Physiol Gastrointest Liver Physiol* 2007; **293**: G1–G4.
- 40 Wolfe RR, Peters EJ. Lipolytic response to glucose infusion in human subjects. *Am J Physiol* 1987; **252**: E218–E223.
- 41 Greenough WB, Crespin SR, Steinberg D. Infusion of long-chain fatty acid anions by continuous-flow centrifugation. *J Clin Invest* 1969; **48**: 1923–1933.
- 42 Mazzeo RS, Brooks GA, Schoeller DA, Budinger TF. Disposal of blood [1-13C]lactate in humans during rest and exercise. *J Appl Physiol* 1986; **60**: 232–241.
- 43 Wolfe RR. Regulation of skeletal muscle protein metabolism in catabolic states. *Curr Opin Clin Nutr Metab Care* 2005; **8**: 61–65.
- 44 Biolo G, Fleming RY, Maggi SP, Wolfe RR. Transmembrane transport and intracellular kinetics of amino acids in human skeletal muscle. *Am J Physiol* 1995; **268**: E75–E84.
- 45 Engelen MP, Rutten EP, De Castro CL, Wouters EF, Schols AM, Deutz NE. Casein protein results in higher prandial and exercise induced whole body protein anabolism than whey protein in chronic obstructive pulmonary disease. *Metab Clin Exp* 2012; **61**: 1289–1300.
- 46 Biolo G, Williams BD, Fleming RY, Wolfe RR. Insulin action on muscle protein kinetics and amino acid transport during recovery after resistance exercise. *Diabetes* 1999; **48**: 949–957.
- 47 Volpi E, Ferrando AA, Yeckel CW, Tipton KD, Wolfe RR. Exogenous amino acids stimulate net muscle protein synthesis in the elderly. *J Clin Invest* 1998; **101**: 2000–2007.
- 48 Biolo G, Chinkes D, Zhang XJ, Wolfe RR., Harry M. Vars Research Award. A new model to determine in vivo the relationship between amino acid transmembrane transport and protein kinetics in muscle. *J Parenter Enteral Nutr* 1992; **16**: 305–315.
- 49 Hines KM, Ford GC, Klaus KA, Irving BA, Ford BL, Johnson KL *et al*. Application of high-resolution mass spectrometry to measure low abundance isotope enrichment in individual muscle proteins. *Anal Bioanal Chem* 2015; **407**: 4045–4052.
- 50 Zhang X-J, Chinkes DL, Wu Z, Martini WZ, Wolfe RR. Fractional synthesis rates of DNA and protein in rabbit skin are not correlated. *J Nutr* 2004; **134**: 2401–2406.
- 51 Kimball SR, Jefferson LS. Mechanisms of translational control in liver and skeletal muscle. *Biochimie* 1994; **76**: 729–736.
- 52 Wolfe RR, Song J, Sun J, Zhang X-J. Total aminoacyl-transfer RNA pool is greater in liver than muscle in rabbits. *J Nutr* 2007; **137**: 2333–2338.
- 53 Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL *et al*. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 2003; **300**: 1140–1142.
- 54 Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. *Am J Physiol* 1999; **277**: E1130–E1141.
- 55 Cree MG, Zwetsloot JJ, Herndon DN, Newcomer BR, Fram RY, Angel C *et al*. Insulin sensitivity is related to fat oxidation and protein kinase C activity in children with acute burn injury. *J Burn Care Res* 2008; **29**: 585–594.
- 56 Zawadzki JK, Wolfe RR, Mott DM, Lillioja S, Howard BV, Bogardus C. Increased rate of Cori cycle in obese subjects with NIDDM and effect of weight reduction. *Diabetes* 1988; **37**: 154–159.
- 57 Wolfe RR, Evans JE, Mullany CJ, Burke JF. Measurement of plasma free fatty acid turnover and oxidation using [1-13C]palmitic acid. *Biomed Mass Spectrom* 1980; **7**: 168–171.
- 58 Trimmer JK, Casazza GA, Horning MA, Brooks GA. Recovery of (13)CO₂ during rest and exercise after [1-(13)C]acetate, [2-(13)C]acetate, and NaH(13)CO₃ infusions. *Am J Physiol Endocrinol Metab* 2001; **281**: E683–E692.
- 59 Wolfe RR, Jahoor F. Recovery of labeled CO₂ during the infusion of C-1- vs C-2-labeled acetate: implications for tracer studies of substrate oxidation. *Am J Clin Nutr* 1990; **51**: 248–252.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies the paper on Experimental & Molecular Medicine website (<http://www.nature.com/emmm>)